Health Topics

Skip navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( Lock Locked padlock icon ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

You Are Here:
Home →
Phlegmasia cerulea dolens
URL of this page: //medlineplus.gov/ency/article/000200.htm

Phlegmasia cerulea dolens

Phlegmasia cerulea dolens is an uncommon, severe form of deep venous thrombosis (blood clots in the vein). It most often occurs in the upper leg.

Causes

Phlegmasia cerulea dolens is preceded by blood clots in a vein, usually a deep vein of the leg.

Symptoms

Severe pain, rapid swelling, and bluish-skin coloring affect the area below the blocked vein.

Possible Complications

Continued clotting can lead to increased swelling. The swelling can interfere with arterial blood flow. This complication is called phlegmasia alba dolens. It causes the skin to turn white. Phlegmasia alba dolens may lead to tissue death (gangrene) and the need for amputation.

When to Contact a Medical Professional

Seek medical help right away if an arm or leg is severely swollen, blue, or painful.

Alternative Names

Deep vein thrombosis - Phlegmasia cerulea dolens; DVT - Phlegmasia cerulea dolens; Phlegmasia alba dolens

Images

References

Johanning J, Thompson JR, Lynch TG. Clinical evaluation of the venous and lymphatic systems. In: Sidawy AN, Perler BA, eds. Rutherford's Vascular Surgery and Endovascular Therapy, 2-Volume Set. 10th ed. Philadelphia, PA: Elsevier; 2023:chap 20.

Kabrhel C. Pulmonary embolism and deep vein thrombosis. In: Walls RM, ed. Rosen's Emergency Medicine: Concepts and Clinical Practice. 10th ed. Philadelphia, PA: Elsevier; 2023:chap 74.

Review Date 3/31/2024

Updated by: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

Related MedlinePlus Health Topics

A.D.A.M., Inc. is accredited by URAC, for Health Content Provider (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process, and privacy policy.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, timeliness, or correctness of any translations made by a third-party service of the information provided herein into any other language.
© 1997- 2026 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
All content on this site including text, images, graphics, audio, video, data, metadata, and compilations is protected by copyright and other intellectual property laws. You may view the content for personal, noncommercial use. Any other use requires prior written consent from Ebix. You may not copy, reproduce, distribute, transmit, display, publish, reverse-engineer, adapt, modify, store beyond ordinary browser caching, index, mine, scrape, or create derivative works from this content. You may not use automated tools to access or extract content, including to create embeddings, vectors, datasets, or indexes for retrieval systems. Use of any content for training, fine-tuning, calibrating, testing, evaluating, or improving AI systems of any kind is prohibited without express written consent. This includes large language models, machine learning models, neural networks, generative systems, retrieval-augmented systems, and any software that ingests content to produce outputs. Any unauthorized use of the content including AI-related use is a violation of our rights and may result in legal action, damages, and statutory penalties to the fullest extent permitted by law. Ebix reserves the right to enforce its rights through legal, technological, and contractual measures.